Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 participants

Journal of the American Academy of Dermatology

Volumn 61, Issue 6, 2009, Pages

  Brin, Mitchell F ^a,b   Boodhoo, Terry I ^a   Pogoda, Janice M ^c   James, Lynn M ^a   Demos, George ^a   Terashima, Yasunori ^e   Gu, Juanhong ^f   Eadie, Nina ^d   Bowen, Beta L ^a  

^a ALLERGAN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d independent contractor   (United States)

^e Development and Medical Affairs Division   (Japan)

^f GLAXOSMITHKLINE   (China)

Author keywords

aesthetic; botulinum toxin; cosmetic; crow's feet; glabellar lines; onabotulinumtoxinA; rhytids; safety; tolerability

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ACNE; ARTICLE; ASIAN; CAUCASIAN; CENTRAL NERVOUS SYSTEM DISEASE; DENTAL CARIES; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE PAIN; EYELID EDEMA; HERPES LABIALIS; HUMAN; INJECTION SITE PRURITUS; LOWER RESPIRATORY TRACT INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PTOSIS; REGISTRATION; RISK BENEFIT ANALYSIS; SENSORY DYSFUNCTION; SYSTEMATIC REVIEW; WEAKNESS; WRINKLE;

EID: 71549160005     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.06.040     Document Type: Article

References (42)

1. American Society for Aesthetic Plastic Surgery. 2007 ASAPS statistics (2008), ASAPS, New York
2. Fagien S., Cox S.E., Finn J.C., Werschler W.P., and Kowalski J.W. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatol Surg 33 (2007) S2-S9
3. Stotland M.A., Kowalski J.W., and Ray B.B. Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: results from a prospective open-label study. Plast Reconstr Surg 120 (2007) 1386-1393
4. Carruthers J.A., Lowe N.J., Menter M.A., Gibson J., Nordquist M., Mordaunt J., et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46 (2002) 840-849
5. Carruthers J.D., Lowe N.J., Menter M.A., Gibson J., and Eadie N. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 112 (2003) 21S-30S
6. Harii K., and Kawashima M. A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plast Surg 32 (2008) 724-730
7. Carruthers A., Carruthers J., Lowe N.J., Menter A., Gibson J., Nordquist M., et al. One-year, randomized, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res 7 (2004) 1-20
8. Lowe N.J., Ascher B., Heckmann M., Kumar C., Fraczek S., and Eadie N. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 31 (2005) 257-262
9. Kawashima M., and Harii K. An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. Int J Dermatol 48 (2009) 768-776
10. International Federation of Pharmaceutical Manufacturers and Associations. MedDRA introductory guide V11.0 (updated March 2008). Chantilly (VA). Available from: URL:http://www.meddramsso.com. Accessed September 22, 2008.
11. Horowitz B.Z. Botulinum toxin. Crit Care Clin 21 (2005) 825-839 viii
12. Sobel J. Botulism. Clin Infect Dis 41 (2005) 1167-1173
13. Kasper D.L., Braunwald E., Fauci A.S., Hauser S.L., Longo D.L., and Jameson J.L. Harrison's principles of internal medicine. 16th ed (2005), Mc-Graw Hill Companies, New York (NY) p. 1157, 1373, 1931
14. National Cancer Institute (Division of Cancer Treatment and Diagnosis), National Institutes of Health, Department of Health and Human Services. Cancer therapy evaluation program, common terminology criteria for adverse events, Version 3.0. Available from: URL:http://ctep.cancer.gov. Accessed September 22, 2008.
15. Mozzicato P. Standardized MedDRA queries: their role in signal detection. Drug Saf 30 (2007) 617-619
16. Yusuf S., Peto R., Lewis J., Collins R., and Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27 (1985) 335-371
17. Sweeting M.J., Sutton A.J., and Lambert P.C. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23 (2004) 1351-1375
18. Cochran W.G. The combination of estimates from different experiments. Biometrics 10 (1954) 101-129
19. Higgins J.P., and Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002) 1539-1558
20. SAS Institute, Inc. SAS/Stat user's guide (2003), SAS Institute Inc, Cary (NC)
21. Breslow N.E., and Day N.E. Classical methods of analysis of grouped data. Statistical methods in cancer research. Vol I. The analysis of case-control studies (IARC Scientific Publications No. 32) (1980), International Agency for Research on Cancer, Lyon p. 122-59
22. Tugnoli V., Capone J.G., Eleopra R., Quatrale R., Sensi M., Gastaldo E., et al. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain 130 (2007) 76-83
23. Gazerani P., Pedersen N.S., Staahl C., Drewes A.M., and Rendt-Nielsen L. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 141 (2009) 60-69
24. Jeong S., Lemke B.N., Dortzbach R.K., Park Y.G., and Kang H.K. The Asian upper eyelid: an anatomical study with comparison to the Caucasian eyelid. Arch Ophthalmol 117 (1999) 907-912
25. McCurdy J.A., and Lam S.M. Asian blepharoplasty. Cosmetic surgery of the Asian face. 2nd ed. (2005), Thieme, New York pp. 8-14
26. Brin M.F., Comella C.L., Jankovic J., Lai F., and Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23 (2008) 1353-1360
27. Defazio G., Abbruzzese G., Girlanda P., Vacca L., Currà A., De Salvia R., et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 59 (2002) 418-420
28. Smith K.C., and Alam M. Botulinum toxin for pain relief and treatment of headache. In: Carruthers A., and Carruthers J. (Eds). Botulinum toxin. 2nd ed (2008), Saunders Elsevier, Philadelphia 93-103
29. Kaneko Y., Motohashi Y., Nakamura H., Endo T., and Eboshida A. Increasing prevalence of Japanese cedar pollinosis: a meta-regression analysis. Int Arch Allergy Immunol 136 (2005) 365-371
30. Jankovic J., Esquenazi A., Fehlings D., Freitag F., Lang A.M., and Naumann M. Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol 27 (2004) 234-244
31. Turkel C.C., Bowen B., Liu J., and Brin M.F. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil 87 (2006) 786-792
32. Cote T.R., Mohan A.K., Polder J.A., Walton M.K., and Braun M.M. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 53 (2005) 407-415
33. Hsiung G.Y., Das S.K., Ranawaya R., Lafontaine A.L., and Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17 (2002) 1288-1293
34. Mejia N.I., Vuong K.D., and Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20 (2005) 592-597
35. Guirguis-Blake J., Calonge N., Miller T., Siu A., Teutsch S., and Whitlock E. Current processes of the US Preventive Services Task Force: refining evidence-based recommendation development. Ann Intern Med 147 (2007) 117-122
36. Food and Drug Administration. Code of Federal Regulations, Title 21, Vol 5 (2008), Government Printing Office, Rockville (MD)
37. Chapman M.A., Barron R., Tanis D.C., Gill C.E., and Charles P.D. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 29 (2007) 1325-1337
38. Wenzel R., Jones D., and Borrego J.A. Comparing two botulinum toxin type A formulations using manufacturers' product summaries. J Clin Pharm Ther 32 (2007) 387-402
39. Anderson T.J., Rivest J., Stell R., Steiger M.J., Cohen H., Thompson P.D., et al. Botulinum toxin treatment of spasmodic torticollis. J R Soc Med 85 (1992) 524-529
40. Brin M.F., and Blitzer A. Botulinum toxin-dangerous terminology errors. [letter]. J R Soc Med 86 (1993) 494
41. Marsden C.D. Botulinum toxin-dangerous terminology errors. [reply]. J R Soc Med 86 (1993) 494
42. Harper L. Botulinum toxin A-when is a unit not a unit?. J Urol 181 (2009) 414-415